대용 인공 혈액 시장 - 세계 및 지역별 분석 : 용도별, 최종 용도별, 제품별, 유래별, 유형별, 구성별, 지역별 - 분석 및 예측(2024-2034년)

Introduction to Synthetic Blood Substitute Market

The synthetic blood substitute market is rapidly emerging as a critical solution to address the limitations of traditional blood transfusions, finding widespread applications across various medical fields globally. With increasing incidences of trauma, surgeries, and chronic diseases, synthetic blood substitutes offer a reliable and safe alternative, ensuring an uninterrupted supply of vital blood components. In an optimistic scenario, the market, valued at $8.7 million in 2024, is anticipated to grow at a CAGR of 15.43%, reaching $36.7 million by 2034.

Increasing medical advancements and a growing need for reliable blood alternatives are driving the demand for synthetic blood substitutes in the healthcare sector. As incidences of trauma, surgeries, and chronic diseases continue to rise, there is a growing necessity for effective and safe blood substitutes that can overcome the limitations of traditional blood transfusions. Synthetic blood substitutes, with their ability to mimic the oxygen-carrying and clotting functions of natural blood, have emerged as a critical solution across applications such as emergency medicine, surgeries, and chronic disease management.

In the synthetic blood substitute market, challenges include high research and development costs and the complexities associated with regulatory approvals. Additionally, ensuring the safety and efficacy of these substitutes in diverse medical conditions adds further complexity to market entry and expansion. However, these challenges promotes innovation and collaboration among biotech firms, healthcare providers, and regulatory bodies, driving the development of more advanced synthetic blood substitutes and expanding their potential applications in modern medicine.

North America, led by the U.S., dominates the synthetic blood substitute market, driven by its advanced biomedical research sector and substantial healthcare infrastructure. U.S. leads in synthetic blood substitute development due to its robust investment in research and development, coupled with strong support from regulatory bodies. This environment promotes innovation, resulting in cutting-edge synthetic blood products that address critical needs in trauma care, surgeries, and chronic disease management. Furthermore, the U.S. commitment to improving healthcare outcomes and addressing blood supply shortages propels the adoption of synthetic blood substitutes across various medical fields. The nation's emphasis on patient safety and technological advancements ensures that synthetic blood substitutes are continually refined for efficacy and reliability. With a focus on enhancing medical care and meeting the increasing demand for blood substitutes, the U.S. solidifies its position as a key player in the global synthetic blood substitute market.

Key players such as Aurum Biosciences, HEMARINA, Hemoglobin Oxygen Therapeutics LLC, and KaloCyte, Inc. are at the forefront of market expansion, utilizing their technological expertise and strategic partnerships to drive innovation and capture a significant market share. Companies are investing in the construction of new production facilities and the expansion of existing ones to meet the growing demand. For instance, in September 2022, VirTech Bio received approximately $13.7 million in funding from the Pentagon and the U.S. Department of Defense (DoD) to advance the clinical research of its hemoglobin-based oxygen-carrying solution, OxyBridge. This product is designed to prevent hemorrhagic shock in trauma patients and enhance the viability of organs donated for transplantation.

Market Segmentation:

Segmentation 1: by Application

• Cardiovascular Diseases
• Malignant Neoplasma
• Injuries
• Neonatal Conditions
• Organ Transplant
• Maternal Condition
• Others

Segmentation 2: by End-use

• Hospitals
• Ambulatory Surgical Centers
• Military and Defense
• Research Laboratories
• Emergency Services
• Others

Segmentation 3: by Product

• Hemoglobin-Based Oxygen Carriers (HBOCs)
• Perfluorocarbon Emulsions (PFCs)
• Stem Cell-Derived Red Blood Cells
• Others

Segmentation 4: by Source

• Human Blood
• Microorganism Based Recombinant HB
• Synthetic Polymers
• Stem Cells
• Others

Segmentation 5: by Component

• Red Blood Cell Substitutes
• Platelet Substitutes
• Plasma Substitutes

Segmentation 6: by Configuration

• Injectable Solutions
• Powdered Forms
• Infusion Bags
• Capsules and Tablets
• Others

Segmentation 7: by Region

• North America
• Europe
• Asia-Pacific
• Rest-of-the-World

How can this report add value to an organization?

Product/Innovation Strategy: The global synthetic blood substitute market has been extensively segmented based on various categories, such as application, end-use, product, source, component, and configuration. This can help readers get a clear overview of which segments account for the largest share and which ones are well-positioned to grow in the coming years.

Competitive Strategy: A detailed competitive benchmarking of the players operating in the global synthetic blood substitute market has been done to help the reader understand how players stack against each other, presenting a clear market landscape. Additionally, comprehensive competitive strategies such as partnerships, agreements, and collaborations will aid the reader in understanding the untapped revenue pockets in the market.

Key Market Players and Competition Synopsis

The companies that are profiled have been selected based on thorough secondary research, which includes analyzing company coverage, product portfolio, market penetration, and insights gathered from primary experts.

Some of the prominent companies in this market are:

• Aurum Biosciences
• HEMARINA
• Hemoglobin Oxygen Therapeutics LLC
• KaloCyte, Inc.
• Spheritech Ltd
• NuvOx Pharma
• Prolong Pharmaceuticals
• Boston Pharmaceuticals

Key Questions Answered in this Report:

• What are the main factors driving the demand for synthetic blood substitute market?
• What are the major patents filed by the companies active in synthetic blood substitute market?
• Who are the key players in the synthetic blood substitute market, and what are their respective market shares?
• What are the strategies adopted by the key companies to gain a competitive edge in synthetic blood substitute market?
• What is the futuristic outlook for the synthetic blood substitute market in terms of growth potential?
• What is the current estimation of the synthetic blood substitute market, and what growth trajectory is projected from 2024 to 2034?
• Which application, and product segment is expected to lead the market over the forecast period (2024-2034)?
• Which regions demonstrate the highest adoption rates for synthetic blood substitute market, and what factors contribute to their leadership?

Table of Contents

Executive Summary

Scope and Definition

Market/Product Definition

Key Questions Answered

Analysis and Forecast Note

1. Markets: Industry Outlook

• 1.1 Trends: Current and Future Impact Assessment
  • 1.1.1 Increasing Demand for Blood Transfusions due to Rising Trauma and Chronic Diseases
  • 1.1.2 Advancement in Stem Cell Technology and Regenerative Medicine
  • 1.1.3 Integration with Advanced Diagnostics and Monitoring
• 1.2 Supply Chain Overview
  • 1.2.1 Value Chain Analysis
  • 1.2.2 Pricing Forecast
• 1.3 R&D Review
  • 1.3.1 Patent Filing Trend by Country, by Company
• 1.4 Regulatory Landscape
• 1.5 Stakeholder Analysis
  • 1.5.1 Use Case
  • 1.5.2 End User and Buying Criteria
• 1.6 Impact Analysis for Key Global Events
• 1.7 Market Dynamics Overview
  • 1.7.1 Market Drivers
  • 1.7.2 Market Restraints
  • 1.7.3 Market Opportunities

2. Synthetic Blood Substitute Market (by Application)

• 2.1 Application Segmentation
• 2.2 Application Summary
• 2.3 Synthetic Blood Substitute Market (by Application)
  • 2.3.1 Cardiovascular Diseases
  • 2.3.2 Malignant Neoplasma
  • 2.3.3 Injuries
  • 2.3.4 Neonatal Conditions
  • 2.3.5 Organ Transplant
  • 2.3.6 Maternal Condition
  • 2.3.7 Others
• 2.4 Synthetic Blood Substitute Market (by End-use)
  • 2.4.1 Hospitals
  • 2.4.2 Ambulatory Surgical Centers
  • 2.4.3 Military and Defense
  • 2.4.4 Research Laboratories
  • 2.4.5 Emergency Services
  • 2.4.6 Others

3. Synthetic Blood Substitute Market (by Product)

• 3.1 Product Segmentation
• 3.2 Product Summary
• 3.3 Synthetic Blood Substitute Market (by Product)
  • 3.3.1 Hemoglobin-Based Oxygen Carriers (HBOCs)
  • 3.3.2 Perfluorocarbon Emulsions (PFCs)
  • 3.3.3 Stem Cell-Derived Red Blood Cells
  • 3.3.4 Others
• 3.4 Synthetic Blood Substitute Market (by Source)
  • 3.4.1 Human Blood
  • 3.4.2 Microorganism Based Recombinant HB
  • 3.4.3 Synthetic Polymers
  • 3.4.4 Stem Cells
  • 3.4.5 Others
• 3.5 Synthetic Blood Substitute Market (by Type)
  • 3.5.1 Red Blood Cell Substitutes
  • 3.5.2 Platelet Substitutes
  • 3.5.3 Plasma Substitutes
• 3.6 Synthetic Blood Substitute Market (by Configuration)
  • 3.6.1 Injectable Solutions
  • 3.6.2 Powdered Forms
  • 3.6.3 Infusion Bags
  • 3.6.4 Capsules and Tablets
  • 3.6.5 Others

4. Synthetic Blood Substitute Market (by Region)

• 4.1 Synthetic Blood Substitute Market (by Region)
• 4.2 North America
  • 4.2.1 Regional Overview
  • 4.2.2 Driving Factors for Market Growth
  • 4.2.3 Factors Challenging the Market
  • 4.2.4 Application
  • 4.2.5 Product
  • 4.2.6 North America Synthetic Blood Substitute Market (by Country)
    • 4.2.6.1 U.S.
      • 4.2.6.1.1 Market by Application
      • 4.2.6.1.2 Market by Product
    • 4.2.6.2 Canada
      • 4.2.6.2.1 Market by Application
      • 4.2.6.2.2 Market by Product
    • 4.2.6.3 Mexico
      • 4.2.6.3.1 Market by Application
      • 4.2.6.3.2 Market by Product
• 4.3 Europe
  • 4.3.1 Regional Overview
  • 4.3.2 Driving Factors for Market Growth
  • 4.3.3 Factors Challenging the Market
  • 4.3.4 Application
  • 4.3.5 Product
  • 4.3.6 Europe Synthetic Blood Substitute Market (by Country)
    • 4.3.6.1 Germany
      • 4.3.6.1.1 Market by Application
      • 4.3.6.1.2 Market by Product
    • 4.3.6.2 France
      • 4.3.6.2.1 Market by Application
      • 4.3.6.2.2 Market by Product
    • 4.3.6.3 U.K.
      • 4.3.6.3.1 Market by Application
      • 4.3.6.3.2 Market by Product
    • 4.3.6.4 Italy
      • 4.3.6.4.1 Market by Application
      • 4.3.6.4.2 Market by Product
    • 4.3.6.5 Rest-of-Europe
      • 4.3.6.5.1 Market by Application
      • 4.3.6.5.2 Market by Product
• 4.4 Asia-Pacific
  • 4.4.1 Regional Overview
  • 4.4.2 Driving Factors for Market Growth
  • 4.4.3 Factors Challenging the Market
  • 4.4.4 Application
  • 4.4.5 Product
  • 4.4.6 Asia-Pacific Synthetic Blood Substitute Market (by Country)
    • 4.4.6.1 China
      • 4.4.6.1.1 Market by Application
      • 4.4.6.1.2 Market by Product
    • 4.4.6.2 Japan
      • 4.4.6.2.1 Market by Application
      • 4.4.6.2.2 Market by Product
    • 4.4.6.3 India
      • 4.4.6.3.1 Market by Application
      • 4.4.6.3.2 Market by Product
    • 4.4.6.4 South Korea
      • 4.4.6.4.1 Market by Application
      • 4.4.6.4.2 Market by Product
    • 4.4.6.5 Rest-of-Asia-Pacific
      • 4.4.6.5.1 Market by Application
      • 4.4.6.5.2 Market by Product
• 4.5 Rest-of-the-World
  • 4.5.1 Regional Overview
  • 4.5.2 Driving Factors for Market Growth
  • 4.5.3 Factors Challenging the Market
  • 4.5.4 Application
  • 4.5.5 Product
  • 4.5.6 Rest-of-the-World Synthetic Blood Substitute Market (by Region)
    • 4.5.6.1 South America
      • 4.5.6.1.1 Market by Application
      • 4.5.6.1.2 Market by Product
    • 4.5.6.2 Middle East and Africa
      • 4.5.6.2.1 Market by Application
      • 4.5.6.2.2 Market by Product

5. Companies Profiled

• 5.1 Next Frontiers
• 5.2 Geographic Assessment
• 5.3 Company Profiles
  • 5.3.1 Aurum Biosciences
    • 5.3.1.1 Overview
    • 5.3.1.2 Top Products/Product Portfolio
    • 5.3.1.3 Top Competitors
    • 5.3.1.4 Target Customers
    • 5.3.1.5 Key Personnel
    • 5.3.1.6 Analyst View
    • 5.3.1.7 Market Share
  • 5.3.2 HEMARINA
    • 5.3.2.1 Overview
    • 5.3.2.2 Top Products/Product Portfolio
    • 5.3.2.3 Top Competitors
    • 5.3.2.4 Target Customers
    • 5.3.2.5 Key Personnel
    • 5.3.2.6 Analyst View
    • 5.3.2.7 Market Share
  • 5.3.3 Hemoglobin Oxygen Therapeutics LLC
    • 5.3.3.1 Overview
    • 5.3.3.2 Top Products/Product Portfolio
    • 5.3.3.3 Top Competitors
    • 5.3.3.4 Target Customers
    • 5.3.3.5 Key Personnel
    • 5.3.3.6 Analyst View
    • 5.3.3.7 Market Share
  • 5.3.4 KaloCyte, Inc.
    • 5.3.4.1 Overview
    • 5.3.4.2 Top Products/Product Portfolio
    • 5.3.4.3 Top Competitors
    • 5.3.4.4 Target Customers
    • 5.3.4.5 Key Personnel
    • 5.3.4.6 Analyst View
    • 5.3.4.7 Market Share
  • 5.3.5 Spheritech Ltd
    • 5.3.5.1 Overview
    • 5.3.5.2 Top Products/Product Portfolio
    • 5.3.5.3 Top Competitors
    • 5.3.5.4 Target Customers
    • 5.3.5.5 Key Personnel
    • 5.3.5.6 Analyst View
    • 5.3.5.7 Market Share
  • 5.3.6 VisusMed Medical Center
    • 5.3.6.1 Overview
    • 5.3.6.2 Top Products/Product Portfolio
    • 5.3.6.3 Top Competitors
    • 5.3.6.4 Target Customers
    • 5.3.6.5 Key Personnel
    • 5.3.6.6 Analyst View
    • 5.3.6.7 Market Share
  • 5.3.7 OPKO Health, Inc.
    • 5.3.7.1 Overview
    • 5.3.7.2 Top Products/Product Portfolio
    • 5.3.7.3 Top Competitors
    • 5.3.7.4 Target Customers
    • 5.3.7.5 Key Personnel
    • 5.3.7.6 Analyst View
    • 5.3.7.7 Market Share
  • 5.3.8 NuvOx Pharma
    • 5.3.8.1 Overview
    • 5.3.8.2 Top Products/Product Portfolio
    • 5.3.8.3 Top Competitors
    • 5.3.8.4 Target Customers
    • 5.3.8.5 Key Personnel
    • 5.3.8.6 Analyst View
    • 5.3.8.7 Market Share
  • 5.3.9 Prolong Pharmaceuticals
    • 5.3.9.1 Overview
    • 5.3.9.2 Top Products/Product Portfolio
    • 5.3.9.3 Top Competitors
    • 5.3.9.4 Target Customers
    • 5.3.9.5 Key Personnel
    • 5.3.9.6 Analyst View
    • 5.3.9.7 Market Share
  • 5.3.10 Boston Pharmaceuticals
    • 5.3.10.1 Overview
    • 5.3.10.2 Top Products/Product Portfolio
    • 5.3.10.3 Top Competitors
    • 5.3.10.4 Target Customers
    • 5.3.10.5 Key Personnel
    • 5.3.10.6 Analyst View
    • 5.3.10.7 Market Share
  • 5.3.11 ATPL
    • 5.3.11.1 Overview
    • 5.3.11.2 Top Products/Product Portfolio
    • 5.3.11.3 Top Competitors
    • 5.3.11.4 Target Customers
    • 5.3.11.5 Key Personnel
    • 5.3.11.6 Analyst View
    • 5.3.11.7 Market Share
  • 5.3.12 Baxter
    • 5.3.12.1 Overview
    • 5.3.12.2 Top Products/Product Portfolio
    • 5.3.12.3 Top Competitors
    • 5.3.12.4 Target Customers
    • 5.3.12.5 Key Personnel
    • 5.3.12.6 Analyst View
    • 5.3.12.7 Market Share
  • 5.3.13 Biopharma corp
    • 5.3.13.1 Overview
    • 5.3.13.2 Top Products/Product Portfolio
    • 5.3.13.3 Top Competitors
    • 5.3.13.4 Target Customers
    • 5.3.13.5 Key Personnel
    • 5.3.13.6 Analyst View
    • 5.3.13.7 Market Share
  • 5.3.14 NORTHFIELD LABORATORIES INC.
    • 5.3.14.1 Overview
    • 5.3.14.2 Top Products/Product Portfolio
    • 5.3.14.3 Top Competitors
    • 5.3.14.4 Target Customers
    • 5.3.14.5 Key Personnel
    • 5.3.14.6 Analyst View
    • 5.3.14.7 Market Share
  • 5.3.15 Alliance Pharma PLC
    • 5.3.15.1 Overview
    • 5.3.15.2 Top Products/Product Portfolio
    • 5.3.15.3 Top Competitors
    • 5.3.15.4 Target Customers
    • 5.3.15.5 Key Personnel
    • 5.3.15.6 Analyst View
    • 5.3.15.7 Market Share
  • 5.3.16 Other Key Companies

6. Research Methodology